Application of Semaphrin7A antibody in preparation of drug for treating myocarditis disease and drug containing Semaphrin7A antibody

A technique for myocarditis and disease, which is applied in the field of preparation of medicines and can solve the problems of lack of effective treatment medicines for myocarditis diseases and the like

Active Publication Date: 2018-05-04
SUZHOU UNIV
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In order to solve the problem of the lack of effective therapeutic drugs for myocarditis diseases in the prior art, the embodiment of the present invention provides the application of a Semaphrin7A antibody in the preparation of drugs for the treatment of myocarditis diseases and its drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Semaphrin7A antibody in preparation of drug for treating myocarditis disease and drug containing Semaphrin7A antibody
  • Application of Semaphrin7A antibody in preparation of drug for treating myocarditis disease and drug containing Semaphrin7A antibody
  • Application of Semaphrin7A antibody in preparation of drug for treating myocarditis disease and drug containing Semaphrin7A antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] The embodiment of the present invention constructs the viral myocarditis model induced by CVB3; The construction steps of the model specifically include:

[0030] (1) Get 6-8 week-old male Balb / c mice, 8 in every group, give each mouse the CVB3 virus of 10 3 TCID50 doses in the mode of intraperitoneal injection respectively, and PBS group is contrast;

[0031] (2) 7 days after virus infection, observe the body weight changes of the mice and analyze and compare the myocarditis indicators with those of the control group.

[0032] like figure 1 Shown is the detection result of myocardial body weight change in CVB3-infected mice. Compared with normal mice, the body weight of CVB3 mice decreases significantly with the time of infection;

[0033] like figure 2 Shown is the result of detection of serum cTnI enzyme activity in myocardial injury of CVB3-infected mice. Compared with the myocarditis index of CVB3-infected mice and the control group, the activity of serum cTnI i...

Embodiment 2

[0054] The embodiment of the present invention constructs the autoimmune myocarditis model induced by the preparation emulsified of myocardial myosin and complete Freund's adjuvant; the construction steps of the model specifically include:

[0055] (1) Take 6-8 week-old male Balb / c mice, 8 in each group, give each mouse myocardial myosin and complete Freund's adjuvant emulsified preparation by subcutaneous injection, and inject Isotype's IgG is the control group;

[0056] (2) 21 days after the subcutaneous injection of the preparation, observe the body weight changes of the mice and analyze and compare the myocarditis indicators with those of the control group, and count the survival of the mice. Compared with the normal group, the mice in the induction group started from the 10th day died, and the survival rate was 50% (4 / 8) on the 21st day, indicating that the autoimmune myocarditis model induced by the preparation of myocardial myosin and complete Freund's adjuvant emulsifi...

Embodiment 3

[0066] The invention further discloses a medicine for treating myocarditis, the active ingredient of which includes Semaphrin7A antibody. Semaphrin7A antibody is a monoclonal antibody. Among them, the Semaphrin7A antibody content is 75-120mg.

[0067] The medicine for treating myocarditis also includes medicine auxiliary material and medicine matrix.

[0068] Specifically, the pharmaceutical auxiliary materials include immune adjuvants, stabilizers, and preservatives.

[0069] Among them, 1% human albumin can be selected as the stabilizer; in practice, maltose, glucose, sorbitol and other carbohydrate biological agent stabilizers are often used.

[0070] The immune adjuvant is a vegetable oil adjuvant, specifically glycerol;

[0071] The preservative was chloroform at a concentration of 0.5%.

[0072] In addition, the pharmaceutical preparations may also contain other customary auxiliary substances or additives.

[0073] In the embodiment of the present invention, antioxi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of a Semaphrin7A antibody in preparation of a drug for treating myocarditis disease, and also discloses the drug containing the Semaphrin7A antibody as an activeingredient for treating the myocarditis disease. In a myocarditis mouse model, a diseased mouse is treated with the Semaphrin7A antibody, myocardial cell inflammation can be relieved, and the survival rate of mice can be increased; the Semaphrin7A antibody has important application prospect and popularization value in research, development and production of the drug for treating the myocarditis.

Description

technical field [0001] The invention belongs to the field of preparation of medicines, and in particular relates to the application of Semaphrin7A antibody in the preparation of medicines for treating myocarditis and medicines thereof. Background technique [0002] Myocarditis is a disease characterized by localized or diffuse inflammatory lesions of the myocardium. Lieberman divided myocarditis into fulminant myocarditis, acute myocarditis, chronic active myocarditis, and chronic persistent myocarditis according to the histological changes and clinical manifestations of myocardial biopsy. The pathophysiological mechanism of myocarditis is unclear. The rat enteroviral myocarditis model shows that the virus enters acutely injured cardiomyocytes and causes myocardial necrosis through replication, exposure of intracellular antigens and activation of the host immune system. This phase lasts for weeks to months and is characterized by activation of virus-specific T lymphocytes,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61P9/00
CPCA61K2039/505C07K16/18
Inventor 熊思东董春升胡静平吴学洁
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap